Allspring Global Investments Holdings LLC Trims Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Allspring Global Investments Holdings LLC lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 17.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 51,791 shares of the company’s stock after selling 10,619 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Teva Pharmaceutical Industries were worth $933,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Janney Montgomery Scott LLC grew its stake in Teva Pharmaceutical Industries by 13.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock worth $19,366,000 after acquiring an additional 164,614 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 53.7% in the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after buying an additional 50,247 shares during the period. Capital Wealth Planning LLC purchased a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $2,169,000. SG Americas Securities LLC lifted its stake in Teva Pharmaceutical Industries by 12.0% in the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock worth $8,613,000 after acquiring an additional 65,529 shares during the period. Finally, Coronation Fund Managers Ltd. purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $1,334,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TEVA. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, UBS Group boosted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Down 0.8 %

TEVA opened at $18.45 on Friday. Teva Pharmaceutical Industries Limited has a twelve month low of $8.42 and a twelve month high of $19.08. The company has a 50-day moving average price of $18.03 and a 200 day moving average price of $16.88. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The company has a market cap of $20.90 billion, a PE ratio of -45.00, a price-to-earnings-growth ratio of 1.29 and a beta of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.